HC Wainwright Issues Positive Forecast for KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) had its price target boosted by investment analysts at HC Wainwright from $20.00 to $27.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the specialty pharmaceutical company's stock. HC Wainwright's price target points to a potential upside of 80.60% from the stock's previous close.

A number of other equities research analysts also recently commented on KALV. Leerink Partners increased their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Monday. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Finally, Jones Trading reissued a "buy" rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $26.29.

KalVista Pharmaceuticals Trading Down 0.7%

NASDAQ:KALV traded down $0.11 during midday trading on Tuesday, hitting $14.95. 3,433,676 shares of the stock were exchanged, compared to its average volume of 546,969. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $15.98. The company has a market capitalization of $743.31 million, a price-to-earnings ratio of -4.02 and a beta of -0.04. The business has a 50-day moving average price of $12.43 and a two-hundred day moving average price of $11.08.

Insider Activity at KalVista Pharmaceuticals

In other news, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, April 9th. The shares were bought at an average cost of $9.42 per share, with a total value of $235,500.00. Following the completion of the transaction, the insider directly owned 5,303,985 shares in the company, valued at $49,963,538.70. This trade represents a 0.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul K. Audhya sold 2,776 shares of the company's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $32,867.84. Following the transaction, the insider directly owned 106,611 shares of the company's stock, valued at $1,262,274.24. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,899 shares of company stock valued at $206,176 over the last quarter. Corporate insiders own 10.50% of the company's stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. Earned Wealth Advisors LLC bought a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at about $44,000. GAMMA Investing LLC raised its stake in KalVista Pharmaceuticals by 567.3% in the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock worth $51,000 after purchasing an additional 3,767 shares in the last quarter. CWM LLC raised its stake in KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock worth $53,000 after purchasing an additional 4,549 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $44,000. Finally, Tower Research Capital LLC TRC raised its position in shares of KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 5,502 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).